FDA warns Health and Natural Beauty USA over CGMP failures and unapproved, misbranded SprinJene OTC toothpastes, including children’s products.
What happened
FDA inspected the Piscataway, New Jersey drug manufacturing facility from October 9 to 15, 2024. It found failures to test high-risk ingredients for DEG/EG, to validate manufacturing processes, and to maintain an adequate quality unit. FDA also reviewed product labels and the company website and found SprinJene toothpastes marketed as unapproved new drugs and misbranded.
What FDA found
The firm did not test incoming glycerin and sorbitol solution, or active ingredients, to verify identity and check for DEG/EG.
21 CFR 211.84(d)(1)The firm lacked adequate written procedures and validation for production and process controls.
21 CFR 211.100(a)The quality unit lacked authority and procedures and failed to ensure stability testing, batch records, and complete laboratory records.
21 CFR 211.22(a) and (d)The products are unapproved new drugs because they are marketed as OTC anticaries, antiplaque, antigingivitis, or desensitizer products without required approval or monograph compliance.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)The products are misbranded because their labeling makes drug claims without meeting applicable requirements.
FD&C Act sections 502(a) and (ee), 21 U.S.C. 352(a) and (ee)
What FDA wants
FDA asks for a detailed response with corrective action plans and documentation. It specifically requires DEG/EG test results from retained high-risk component lots no later than 30 calendar days from the letter date.
Who should pay attention
- brands that buy OTC toothpastes from contract manufacturers
- retailers and distributors selling SprinJene products
- quality teams at oral-care companies using glycerin or sorbitol
This is a summary. Read the original letter on fda.gov.